Imatinib in the treatment of chronic myeloid leukemia: current perspectives on optimal dose
Joanna Waclaw,1 Tomasz Sacha,1 Tomasz Stoklosa,21Department of Hematology, Jagiellonian University Collegium Medicum, Kraków, 2Department of Immunology, Medical University of Warsaw, Warsaw, Poland Abstract: Imatinib was the first tyrosine kinase inhibitor (TKI), successfully used in a c...
Guardado en:
Autores principales: | Waclaw J, Sacha T, Stoklosa T |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9962693a876d47368bf62bed7aa6b1bc |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients
por: Natalia Estrada, et al.
Publicado: (2021) -
Long-term safety and efficacy of dasatinib in the treatment of chronic-phase chronic myeloid leukemia patients resistant or intolerant to imatinib
por: Shoumariyeh K, et al.
Publicado: (2014) -
Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives [Erratum]
por: Anagnostou T, et al.
Publicado: (2018) -
PONATINIB EXPERIENCE IN A PEDIATRIC CHRONIC MYELOID LEUKEMIA PATIENT
por: Serap Karaman, et al.
Publicado: (2021) -
SECONDARY CHRONIC MYELOID LEUKEMIA FOLLOWING RADIOACTIVE IODINE (I131)
por: Yousef Hailan, et al.
Publicado: (2021)